成立年份: 1949
总资产(USD): 不愿意公开
员工总人数: 500以上
主要竞争优势: 品牌,优质服务
其他竞争优势:
专利与版权:
业务类型: 制造商
年销售额(USD): 不愿意公开
主要销售市场: 北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
主要产品类别: 原料药
所有产品:
氨基酸
外销比重:
内销比重:
主要客户:
合同定制:
付款条款:
1949Establishment of Kyowa Hakko Kogyo1951Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co.,Inc.and succeeded in its mass production1956Success of isolation and commercially mass-production of the anticanser drug,MitomycinC.
Invention of the process of L-Glutamic acid production by fermentation(a world first)
Pioneered the major business industry of amino-acid fermentation.1958Invention of the process of L-Lysin production by fermentation.
Release of a plant growth regulator,Gibberellin Kyowa(Contribution to production of seedless grapes)1969Establishment of Kyowa Hakko USA1973Establishment of Kyowa Hakko Europe1981Establishment of the Bio Business Headquarters2005Completion of the transition to an operating holding company(Phamaceuticals and Bio-chemicals are its main pillars)2007Announced a strategic alliance between Kyowa Hakko Group and Kirin Group.
[Kyowa Hakko Bio]
2008Establishment of Kyowa Hakko Bio
(succeed Bio-Chemical business from Kyowa Hakko Kogyo)
1956年首创用发酵方法生产L-谷氨酸 1988年成立北京事务所